美国强直性脊柱炎患者生物制剂的治疗模式：来自索赔数据库的描述性分析。
Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.
机构信息
University of Utah & Salt Lake City Veterans Affairs Medical Center, Division of Rheumatology, Salt Lake City, UT 84132, USA.
Optum, Eden Prairie, MN 55344, USA.
出版信息
J Comp Eff Res. 2018 Apr;7(4):369-380. doi: 10.2217/cer-2017-0076. Epub 2017 Nov 17.
AIM
Examine treatment patterns among patients with active ankylosing spondylitis (AS) treated with a TNF inhibitor (TNFi).
PATIENTS & METHODS: Patients with AS who initiated a TNFi between 1 January 2013, and 31 January 2015, were identified in the Optum Research Database. Outcomes included adherence, persistence, discontinuation and therapy modifications of the index TNFi during 12-month follow-up.
RESULTS
Of the 426 patients included, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication.
CONCLUSION
A high proportion of patients with AS switched, discontinued or modified their TNFi therapy.
目的
研究接受肿瘤坏死因子抑制剂（TNFi）治疗的活动期强直性脊柱炎（AS）患者的治疗模式。
方法
在 Optum Research Database 中确定了 2013 年 1 月 1 日至 2015 年 1 月 31 日期间开始使用 TNFi 的 AS 患者。结果包括在 12 个月的随访期间，指数 TNFi 的依从性、持续性、停药和治疗改变。
结果
在纳入的 426 名患者中，40.6%的患者持续使用指数 TNFi ≥12 个月，31.0%的患者停药，21.4%的患者改用不同的 TNFi，7.0%的患者停药后再重新开始治疗。在持续使用 TNFi >90 天的 333 名患者中，44.7%的患者接受了至少一种附加药物治疗。
结论
相当一部分 AS 患者改变、停止或调整了他们的 TNFi 治疗。
Zotero 插件